2025-08-29 18:33:23,645 INFO User asked: What are the treatment options for recurrent MSI-H endometrial cancer after progression on pembrolizumab?
2025-08-29 18:33:23,647 INFO Calling ask_question for sample question...
2025-08-29 18:33:44,617 INFO HTTP Request: POST https://az-openai-cancel-poc-001.openai.azure.com/openai/deployments/gpt-4.1/chat/completions?api-version=2024-08-01-preview "HTTP/1.1 200 OK"
2025-08-29 18:33:44,684 INFO Response received: {'messages': [HumanMessage(content='What are the treatment options for recurrent MSI-H endometrial cancer after progression on pembrolizumab?', id='11ad28c9-5045-4560-9b06-e5427a7e59e2'), AIMessage(content='Thank you for your question. I understand how challenging it can be to navigate treatment options after a cancer has progressed, especially when it’s already been treated with immunotherapy like pembrolizumab.\n\n**MSI-H (microsatellite instability-high) endometrial cancer** is a type that often responds well to immunotherapy, but sometimes the cancer can become resistant or progress despite treatment. When this happens, the next steps depend on several factors, including your overall health, previous treatments, and specific characteristics of your cancer.\n\n### Possible Treatment Options After Progression on Pembrolizumab\n\n1. **Chemotherapy**\n   - Traditional chemotherapy drugs (such as carboplatin, paclitaxel, or doxorubicin) may be considered, especially if they haven’t been used before or if there was a long interval since prior chemotherapy.\n\n2. **Targeted Therapy**\n   - **Lenvatinib plus pembrolizumab:** If pembrolizumab was used alone, sometimes it is combined with lenvatinib, a targeted therapy, as this combination has shown benefit in some patients with advanced endometrial cancer.\n   - **Other targeted agents:** Depending on the tumor’s genetic profile, other drugs targeting specific mutations (like PI3K/AKT/mTOR inhibitors) may be considered, though these are often in clinical trials.\n\n3. **Clinical Trials**\n   - Participation in a clinical trial may offer access to new therapies, such as novel immunotherapies, targeted drugs, or combinations that are not yet widely available.\n\n4. **Hormonal Therapy**\n   - For certain types of endometrial cancer (especially if the tumor is hormone receptor-positive), hormonal therapies like progestins or aromatase inhibitors may be an option.\n\n5. **Radiation Therapy**\n   - If the recurrence is localized, radiation therapy may help control symptoms or reduce tumor size.\n\n6. **Supportive and Palliative Care**\n   - If further active treatment is not possible or desired, supportive care can help manage symptoms and maintain quality of life.\n\n### Next Steps\n\n- **Consult your oncology team:** They can review your specific case, including prior treatments and tumor characteristics, to recommend the best options.\n- **Ask about genetic testing:** Sometimes, additional molecular profiling can uncover new targets for therapy.\n- **Consider a second opinion:** Especially at a cancer center with expertise in gynecologic cancers.\n\n### Hopeful Advances\n\nResearch in MSI-H endometrial cancer is ongoing, and new therapies are being developed. Clinical trials are a promising avenue, and many patients find hope and options through participation.\n\n---\n\nIf you’d like, I can help you find clinical trials or more information about specific therapies. Please let me know if you have more details about your situation or any preferences, and I’ll do my best to support you.', response_metadata={'token_usage': {'completion_tokens': 573, 'prompt_tokens': 387, 'total_tokens': 960, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-2025-04-14', 'system_fingerprint': 'fp_c79ab13e31', 'prompt_filter_results': [{'prompt_index': 0, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'jailbreak': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}], 'finish_reason': 'stop', 'logprobs': None, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'protected_material_code': {'filtered': False, 'detected': False}, 'protected_material_text': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}, id='run-305230c0-8f02-4d4b-b9de-2f100ce7c56e-0')]}
2025-08-29 18:33:44,688 INFO LLM response: Thank you for your question. I understand how challenging it can be to navigate treatment options after a cancer has progressed, especially when it’s already been treated with immunotherapy like pembrolizumab.

**MSI-H (microsatellite instability-high) endometrial cancer** is a type that often responds well to immunotherapy, but sometimes the cancer can become resistant or progress despite treatment. When this happens, the next steps depend on several factors, including your overall health, previous treatments, and specific characteristics of your cancer.

### Possible Treatment Options After Progression on Pembrolizumab

1. **Chemotherapy**
   - Traditional chemotherapy drugs (such as carboplatin, paclitaxel, or doxorubicin) may be considered, especially if they haven’t been used before or if there was a long interval since prior chemotherapy.

2. **Targeted Therapy**
   - **Lenvatinib plus pembrolizumab:** If pembrolizumab was used alone, sometimes it is combined with lenvatinib, a targeted therapy, as this combination has shown benefit in some patients with advanced endometrial cancer.
   - **Other targeted agents:** Depending on the tumor’s genetic profile, other drugs targeting specific mutations (like PI3K/AKT/mTOR inhibitors) may be considered, though these are often in clinical trials.

3. **Clinical Trials**
   - Participation in a clinical trial may offer access to new therapies, such as novel immunotherapies, targeted drugs, or combinations that are not yet widely available.

4. **Hormonal Therapy**
   - For certain types of endometrial cancer (especially if the tumor is hormone receptor-positive), hormonal therapies like progestins or aromatase inhibitors may be an option.

5. **Radiation Therapy**
   - If the recurrence is localized, radiation therapy may help control symptoms or reduce tumor size.

6. **Supportive and Palliative Care**
   - If further active treatment is not possible or desired, supportive care can help manage symptoms and maintain quality of life.

### Next Steps

- **Consult your oncology team:** They can review your specific case, including prior treatments and tumor characteristics, to recommend the best options.
- **Ask about genetic testing:** Sometimes, additional molecular profiling can uncover new targets for therapy.
- **Consider a second opinion:** Especially at a cancer center with expertise in gynecologic cancers.

### Hopeful Advances

Research in MSI-H endometrial cancer is ongoing, and new therapies are being developed. Clinical trials are a promising avenue, and many patients find hope and options through participation.

---

If you’d like, I can help you find clinical trials or more information about specific therapies. Please let me know if you have more details about your situation or any preferences, and I’ll do my best to support you.
2025-08-29 19:55:19,035 INFO User asked: What are the treatment options for recurrent MSI-H endometrial cancer after progression on pembrolizumab?
2025-08-29 19:55:19,037 INFO Calling ask_question for sample question...
2025-08-29 19:55:33,813 INFO HTTP Request: POST https://az-openai-cancel-poc-001.openai.azure.com/openai/deployments/gpt-4.1/chat/completions?api-version=2024-08-01-preview "HTTP/1.1 200 OK"
2025-08-29 19:55:33,835 INFO Response received: {'messages': [HumanMessage(content='What are the treatment options for recurrent MSI-H endometrial cancer after progression on pembrolizumab?', id='cf50bb84-1f72-490b-a323-fb22a0740a7c'), AIMessage(content='Thank you for your question. I understand how challenging it can be to navigate treatment decisions after a recurrence, especially when previous therapies like pembrolizumab have not been effective.\n\n**Microsatellite instability-high (MSI-H) endometrial cancer** is known to respond well to immunotherapy, such as pembrolizumab. However, if the cancer progresses despite this treatment, there are still options to consider. Here’s an overview:\n\n### 1. **Clinical Trials**\n- **Why consider?** Clinical trials often offer access to new therapies, including novel immunotherapies, targeted drugs, or combination treatments.\n- **Next step:** Ask your oncologist about ongoing trials for MSI-H endometrial cancer in your area.\n\n### 2. **Other Immunotherapies**\n- **Combination therapies:** Sometimes, pembrolizumab is combined with other agents (like lenvatinib, a targeted therapy). If pembrolizumab was used alone, this combination might be considered.\n- **Alternative checkpoint inhibitors:** Other drugs in the same class (such as nivolumab) may be options, though evidence is limited after progression on pembrolizumab.\n\n### 3. **Targeted Therapies**\n- **Lenvatinib (with pembrolizumab):** If not already tried, this combination is approved for certain advanced endometrial cancers.\n- **Other targeted agents:** Depending on the tumor’s genetic profile, drugs targeting specific mutations (like PI3K, AKT, or mTOR inhibitors) may be considered.\n\n### 4. **Chemotherapy**\n- **Standard regimens:** If immunotherapy and targeted therapy are not effective, traditional chemotherapy (such as carboplatin and paclitaxel) may be used.\n- **Other agents:** Doxorubicin, cisplatin, or other drugs may be options depending on prior treatments and overall health.\n\n### 5. **Hormonal Therapy**\n- **For certain cases:** If the tumor expresses hormone receptors (estrogen or progesterone), hormonal therapies like progestins or tamoxifen may be considered.\n\n### 6. **Supportive and Palliative Care**\n- **Focus on quality of life:** Symptom management, pain control, and emotional support are always important, regardless of treatment stage.\n\n---\n\n**Next Steps:**\n- **Discuss with your oncologist:** They can help tailor options based on your specific situation, prior treatments, and overall health.\n- **Genetic testing:** If not already done, further molecular profiling may reveal new targets for therapy.\n- **Support resources:** Consider connecting with support groups or counseling for emotional and practical support.\n\n**Hopeful note:** Research in MSI-H cancers is active, and new treatments are emerging. Staying informed and connected with your care team can help you access the best options available.\n\nIf you’d like, I can help you find clinical trials or more information about any of these treatments. Please let me know how I can support you further.', response_metadata={'token_usage': {'completion_tokens': 605, 'prompt_tokens': 387, 'total_tokens': 992, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-2025-04-14', 'system_fingerprint': 'fp_c79ab13e31', 'prompt_filter_results': [{'prompt_index': 0, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'jailbreak': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}], 'finish_reason': 'stop', 'logprobs': None, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'protected_material_code': {'filtered': False, 'detected': False}, 'protected_material_text': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}, id='run-b50d83a9-b33f-485b-99cb-0e6229ba58b4-0')]}
2025-08-29 19:55:33,836 INFO LLM response: Thank you for your question. I understand how challenging it can be to navigate treatment decisions after a recurrence, especially when previous therapies like pembrolizumab have not been effective.

**Microsatellite instability-high (MSI-H) endometrial cancer** is known to respond well to immunotherapy, such as pembrolizumab. However, if the cancer progresses despite this treatment, there are still options to consider. Here’s an overview:

### 1. **Clinical Trials**
- **Why consider?** Clinical trials often offer access to new therapies, including novel immunotherapies, targeted drugs, or combination treatments.
- **Next step:** Ask your oncologist about ongoing trials for MSI-H endometrial cancer in your area.

### 2. **Other Immunotherapies**
- **Combination therapies:** Sometimes, pembrolizumab is combined with other agents (like lenvatinib, a targeted therapy). If pembrolizumab was used alone, this combination might be considered.
- **Alternative checkpoint inhibitors:** Other drugs in the same class (such as nivolumab) may be options, though evidence is limited after progression on pembrolizumab.

### 3. **Targeted Therapies**
- **Lenvatinib (with pembrolizumab):** If not already tried, this combination is approved for certain advanced endometrial cancers.
- **Other targeted agents:** Depending on the tumor’s genetic profile, drugs targeting specific mutations (like PI3K, AKT, or mTOR inhibitors) may be considered.

### 4. **Chemotherapy**
- **Standard regimens:** If immunotherapy and targeted therapy are not effective, traditional chemotherapy (such as carboplatin and paclitaxel) may be used.
- **Other agents:** Doxorubicin, cisplatin, or other drugs may be options depending on prior treatments and overall health.

### 5. **Hormonal Therapy**
- **For certain cases:** If the tumor expresses hormone receptors (estrogen or progesterone), hormonal therapies like progestins or tamoxifen may be considered.

### 6. **Supportive and Palliative Care**
- **Focus on quality of life:** Symptom management, pain control, and emotional support are always important, regardless of treatment stage.

---

**Next Steps:**
- **Discuss with your oncologist:** They can help tailor options based on your specific situation, prior treatments, and overall health.
- **Genetic testing:** If not already done, further molecular profiling may reveal new targets for therapy.
- **Support resources:** Consider connecting with support groups or counseling for emotional and practical support.

**Hopeful note:** Research in MSI-H cancers is active, and new treatments are emerging. Staying informed and connected with your care team can help you access the best options available.

If you’d like, I can help you find clinical trials or more information about any of these treatments. Please let me know how I can support you further.
2025-08-31 11:44:55,552 INFO User asked: Can you explain the role of BRCA1/2 mutations in selecting between PARP inhibitors and chemotherapy for metastatic breast cancer?
2025-08-31 11:44:55,564 INFO Calling ask_question for sample question...
2025-08-31 11:45:05,032 INFO HTTP Request: POST https://az-openai-cancel-poc-001.openai.azure.com/openai/deployments/gpt-4.1/chat/completions?api-version=2024-08-01-preview "HTTP/1.1 200 OK"
2025-08-31 11:45:05,049 INFO Response received: {'messages': [HumanMessage(content='Can you explain the role of BRCA1/2 mutations in selecting between PARP inhibitors and chemotherapy for metastatic breast cancer?', id='bd62d574-2d6a-40d6-80f7-76166e6de404'), AIMessage(content='Absolutely, and thank you for asking such an important question. Understanding the role of BRCA1 and BRCA2 mutations can help guide treatment choices for metastatic breast cancer, and I’m here to break it down in a clear and supportive way.\n\n**BRCA1/2 Mutations: What Are They?**  \nBRCA1 and BRCA2 are genes that help repair damaged DNA. When these genes are mutated, cells lose some ability to fix DNA damage, which can lead to cancer. People with inherited (germline) BRCA1 or BRCA2 mutations have a higher risk of developing certain cancers, including breast cancer.\n\n**Why Do BRCA Mutations Matter in Treatment?**  \nThese mutations make cancer cells more vulnerable to treatments that further damage DNA or block DNA repair. This is where PARP inhibitors and chemotherapy come in:\n\n### PARP Inhibitors\n- **How They Work:** PARP inhibitors (like olaparib and talazoparib) block another DNA repair pathway. In BRCA-mutated cancer cells, this double hit (BRCA mutation + PARP inhibition) causes so much DNA damage that the cancer cell dies.\n- **Who Benefits Most:** People with metastatic breast cancer who have a confirmed BRCA1 or BRCA2 mutation may benefit significantly from PARP inhibitors.\n- **Advantages:** These drugs are often taken as pills, may have different side effects than chemotherapy, and can be effective in slowing cancer progression in BRCA-mutated cases.\n\n### Chemotherapy\n- **How It Works:** Chemotherapy kills rapidly dividing cells, including cancer cells, by damaging their DNA.\n- **Role in BRCA-Mutated Cancer:** Chemotherapy is still effective for BRCA-mutated cancers, but it’s less targeted than PARP inhibitors.\n- **When Used:** Chemotherapy may be used if PARP inhibitors aren’t suitable, if the cancer progresses on PARP inhibitors, or in combination with other treatments.\n\n### How Is the Choice Made?\n- **Genetic Testing:** If you have metastatic breast cancer, your doctor may recommend genetic testing for BRCA mutations. The presence of a mutation can make you eligible for PARP inhibitors.\n- **Other Factors:** The choice also depends on previous treatments, overall health, side effect profiles, and personal preferences.\n\n### What’s the Evidence?\nClinical studies have shown that PARP inhibitors can improve progression-free survival (the time the cancer is controlled) in people with BRCA-mutated metastatic breast cancer compared to some standard chemotherapies.\n\n---\n\n**Next Steps:**\n- If you or a loved one has metastatic breast cancer, ask your care team about genetic testing for BRCA mutations.\n- Discuss the pros and cons of PARP inhibitors versus chemotherapy with your oncologist.\n- Consider joining support groups or seeking counseling to help navigate these decisions.\n\n**Hopeful Insight:**  \nAdvances like PARP inhibitors are a result of understanding the genetics of cancer, and they offer new, more personalized options for treatment.\n\nIf you have more questions or want to know about side effects, eligibility, or how to talk to your doctor, I’m here to help.', response_metadata={'token_usage': {'completion_tokens': 634, 'prompt_tokens': 391, 'total_tokens': 1025, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-2025-04-14', 'system_fingerprint': 'fp_c79ab13e31', 'prompt_filter_results': [{'prompt_index': 0, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'jailbreak': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}], 'finish_reason': 'stop', 'logprobs': None, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'protected_material_code': {'filtered': False, 'detected': False}, 'protected_material_text': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}, id='run-85a0052c-6829-48aa-bcc1-2d3c126b06f3-0')]}
2025-08-31 11:45:05,051 INFO LLM response: Absolutely, and thank you for asking such an important question. Understanding the role of BRCA1 and BRCA2 mutations can help guide treatment choices for metastatic breast cancer, and I’m here to break it down in a clear and supportive way.

**BRCA1/2 Mutations: What Are They?**  
BRCA1 and BRCA2 are genes that help repair damaged DNA. When these genes are mutated, cells lose some ability to fix DNA damage, which can lead to cancer. People with inherited (germline) BRCA1 or BRCA2 mutations have a higher risk of developing certain cancers, including breast cancer.

**Why Do BRCA Mutations Matter in Treatment?**  
These mutations make cancer cells more vulnerable to treatments that further damage DNA or block DNA repair. This is where PARP inhibitors and chemotherapy come in:

### PARP Inhibitors
- **How They Work:** PARP inhibitors (like olaparib and talazoparib) block another DNA repair pathway. In BRCA-mutated cancer cells, this double hit (BRCA mutation + PARP inhibition) causes so much DNA damage that the cancer cell dies.
- **Who Benefits Most:** People with metastatic breast cancer who have a confirmed BRCA1 or BRCA2 mutation may benefit significantly from PARP inhibitors.
- **Advantages:** These drugs are often taken as pills, may have different side effects than chemotherapy, and can be effective in slowing cancer progression in BRCA-mutated cases.

### Chemotherapy
- **How It Works:** Chemotherapy kills rapidly dividing cells, including cancer cells, by damaging their DNA.
- **Role in BRCA-Mutated Cancer:** Chemotherapy is still effective for BRCA-mutated cancers, but it’s less targeted than PARP inhibitors.
- **When Used:** Chemotherapy may be used if PARP inhibitors aren’t suitable, if the cancer progresses on PARP inhibitors, or in combination with other treatments.

### How Is the Choice Made?
- **Genetic Testing:** If you have metastatic breast cancer, your doctor may recommend genetic testing for BRCA mutations. The presence of a mutation can make you eligible for PARP inhibitors.
- **Other Factors:** The choice also depends on previous treatments, overall health, side effect profiles, and personal preferences.

### What’s the Evidence?
Clinical studies have shown that PARP inhibitors can improve progression-free survival (the time the cancer is controlled) in people with BRCA-mutated metastatic breast cancer compared to some standard chemotherapies.

---

**Next Steps:**
- If you or a loved one has metastatic breast cancer, ask your care team about genetic testing for BRCA mutations.
- Discuss the pros and cons of PARP inhibitors versus chemotherapy with your oncologist.
- Consider joining support groups or seeking counseling to help navigate these decisions.

**Hopeful Insight:**  
Advances like PARP inhibitors are a result of understanding the genetics of cancer, and they offer new, more personalized options for treatment.

If you have more questions or want to know about side effects, eligibility, or how to talk to your doctor, I’m here to help.
2025-08-31 11:47:36,912 INFO User asked: How does the presence of a TP53 mutation impact the prognosis and treatment strategy in high-grade serous ovarian cancer?
2025-08-31 11:47:36,913 INFO Calling ask_question for sample question...
2025-08-31 11:47:43,235 INFO HTTP Request: POST https://az-openai-cancel-poc-001.openai.azure.com/openai/deployments/gpt-4.1/chat/completions?api-version=2024-08-01-preview "HTTP/1.1 200 OK"
2025-08-31 11:47:43,245 INFO Response received: {'messages': [HumanMessage(content='How does the presence of a TP53 mutation impact the prognosis and treatment strategy in high-grade serous ovarian cancer?', id='fb566e16-2e1f-4009-b701-dbc1fef7e663'), AIMessage(content='Thank you for your thoughtful question. The TP53 gene plays a crucial role in regulating cell growth and preventing cancer. Mutations in TP53 are very common in high-grade serous ovarian cancer (HGSOC)—in fact, more than 95% of these cases have TP53 mutations.\n\n**Impact on Prognosis:**\n- The presence of a TP53 mutation is considered a hallmark of HGSOC, so it doesn’t necessarily make the prognosis worse compared to other HGSOC cases, since almost all patients with this subtype have it.\n- TP53 mutations are associated with aggressive tumor behavior, but in HGSOC, their presence is expected and does not by itself distinguish between better or worse outcomes within this group.\n- Other factors, such as stage at diagnosis, response to chemotherapy, and presence of additional mutations (like BRCA1/2), have a greater impact on prognosis.\n\n**Impact on Treatment Strategy:**\n- Standard treatment for HGSOC (regardless of TP53 status) typically includes surgery and platinum-based chemotherapy.\n- TP53 mutations themselves do not currently guide specific targeted therapies in ovarian cancer, but research is ongoing to find drugs that exploit the vulnerabilities caused by TP53 loss.\n- The presence of other mutations (such as BRCA1/2) may open up additional treatment options, like PARP inhibitors, which are not directly related to TP53 status.\n- Clinical trials are exploring therapies that target pathways affected by TP53 mutations, but these are not yet standard care.\n\n**Next Steps:**\n- If you or a loved one is facing HGSOC, it’s important to discuss genetic testing for other mutations (like BRCA) with your care team, as these can influence treatment choices.\n- Staying informed about clinical trials and new research may offer additional options in the future.\n\n**Hopeful Insights:**\n- Advances in understanding the genetics of ovarian cancer are leading to more personalized treatments and better outcomes.\n- Support groups and counseling can help with the emotional challenges of diagnosis and treatment.\n\nIf you have more specific questions about genetic testing, treatment options, or support resources, I’m here to help guide you.', response_metadata={'token_usage': {'completion_tokens': 433, 'prompt_tokens': 389, 'total_tokens': 822, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-2025-04-14', 'system_fingerprint': 'fp_c79ab13e31', 'prompt_filter_results': [{'prompt_index': 0, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'jailbreak': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}], 'finish_reason': 'stop', 'logprobs': None, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'protected_material_code': {'filtered': False, 'detected': False}, 'protected_material_text': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}, id='run-bfcc810c-0c9c-476d-9350-310c6d665f5e-0')]}
2025-08-31 11:47:43,249 INFO LLM response: Thank you for your thoughtful question. The TP53 gene plays a crucial role in regulating cell growth and preventing cancer. Mutations in TP53 are very common in high-grade serous ovarian cancer (HGSOC)—in fact, more than 95% of these cases have TP53 mutations.

**Impact on Prognosis:**
- The presence of a TP53 mutation is considered a hallmark of HGSOC, so it doesn’t necessarily make the prognosis worse compared to other HGSOC cases, since almost all patients with this subtype have it.
- TP53 mutations are associated with aggressive tumor behavior, but in HGSOC, their presence is expected and does not by itself distinguish between better or worse outcomes within this group.
- Other factors, such as stage at diagnosis, response to chemotherapy, and presence of additional mutations (like BRCA1/2), have a greater impact on prognosis.

**Impact on Treatment Strategy:**
- Standard treatment for HGSOC (regardless of TP53 status) typically includes surgery and platinum-based chemotherapy.
- TP53 mutations themselves do not currently guide specific targeted therapies in ovarian cancer, but research is ongoing to find drugs that exploit the vulnerabilities caused by TP53 loss.
- The presence of other mutations (such as BRCA1/2) may open up additional treatment options, like PARP inhibitors, which are not directly related to TP53 status.
- Clinical trials are exploring therapies that target pathways affected by TP53 mutations, but these are not yet standard care.

**Next Steps:**
- If you or a loved one is facing HGSOC, it’s important to discuss genetic testing for other mutations (like BRCA) with your care team, as these can influence treatment choices.
- Staying informed about clinical trials and new research may offer additional options in the future.

**Hopeful Insights:**
- Advances in understanding the genetics of ovarian cancer are leading to more personalized treatments and better outcomes.
- Support groups and counseling can help with the emotional challenges of diagnosis and treatment.

If you have more specific questions about genetic testing, treatment options, or support resources, I’m here to help guide you.
2025-08-31 11:57:21,718 INFO User asked: How does tumor mutational burden influence the choice of immunotherapy in non-small cell lung cancer with negative PD-L1 expression?
2025-08-31 11:57:21,721 INFO Calling ask_question for sample question...
2025-08-31 11:57:29,193 INFO HTTP Request: POST https://az-openai-cancel-poc-001.openai.azure.com/openai/deployments/gpt-4.1/chat/completions?api-version=2024-08-01-preview "HTTP/1.1 200 OK"
2025-08-31 11:57:29,199 INFO Response received: {'messages': [HumanMessage(content='How does tumor mutational burden influence the choice of immunotherapy in non-small cell lung cancer with negative PD-L1 expression?', id='b2424493-12be-485d-a7d6-672f292633ce'), AIMessage(content='Thank you for your thoughtful question. Tumor mutational burden (TMB) and PD-L1 expression are both important biomarkers that can help guide immunotherapy decisions in non-small cell lung cancer (NSCLC). Let me explain how TMB can influence treatment, especially when PD-L1 is negative.\n\n**What is Tumor Mutational Burden (TMB)?**  \nTMB refers to the number of mutations found within the DNA of cancer cells. A high TMB means the tumor has many genetic changes, which can make it more recognizable to the immune system.\n\n**PD-L1 Expression and Immunotherapy**  \nPD-L1 is a protein that some cancer cells use to hide from the immune system. Immunotherapies like checkpoint inhibitors (e.g., pembrolizumab, nivolumab) often work better when PD-L1 is present on tumor cells. However, some patients have tumors that are PD-L1 negative, meaning these drugs may be less effective.\n\n**Role of TMB When PD-L1 is Negative**  \n- **High TMB:** Research suggests that even if PD-L1 is negative, a high TMB may predict a better response to immunotherapy. This is because the immune system may still recognize and attack tumors with many mutations, even without PD-L1 expression.\n- **Low TMB:** If both PD-L1 and TMB are low, the likelihood of responding to immunotherapy is generally lower.\n\n**Clinical Decision-Making**  \n- In cases of NSCLC with negative PD-L1, oncologists may consider TMB testing. If TMB is high, immunotherapy (sometimes in combination with other treatments) might still be recommended.\n- If TMB is low, other treatment options like chemotherapy or targeted therapy may be preferred.\n\n**Important Note**  \nWhile TMB is a promising biomarker, it is not yet universally used in clinical practice, and guidelines are evolving. Decisions are made based on a combination of factors, including overall health, cancer stage, and other molecular markers.\n\n**Next Steps**  \nIf you or a loved one is facing this situation, discussing TMB testing and treatment options with your oncology team is important. They can provide personalized recommendations based on the latest research and your specific case.\n\nIf you’d like, I can share more about recent advances or support resources for NSCLC patients. Please let me know how I can help further.', response_metadata={'token_usage': {'completion_tokens': 484, 'prompt_tokens': 391, 'total_tokens': 875, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-2025-04-14', 'system_fingerprint': 'fp_c79ab13e31', 'prompt_filter_results': [{'prompt_index': 0, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'jailbreak': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}], 'finish_reason': 'stop', 'logprobs': None, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'protected_material_code': {'filtered': False, 'detected': False}, 'protected_material_text': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}, id='run-53a74649-732d-4347-a30d-d8639d67918c-0')]}
2025-08-31 11:57:29,200 INFO LLM response: Thank you for your thoughtful question. Tumor mutational burden (TMB) and PD-L1 expression are both important biomarkers that can help guide immunotherapy decisions in non-small cell lung cancer (NSCLC). Let me explain how TMB can influence treatment, especially when PD-L1 is negative.

**What is Tumor Mutational Burden (TMB)?**  
TMB refers to the number of mutations found within the DNA of cancer cells. A high TMB means the tumor has many genetic changes, which can make it more recognizable to the immune system.

**PD-L1 Expression and Immunotherapy**  
PD-L1 is a protein that some cancer cells use to hide from the immune system. Immunotherapies like checkpoint inhibitors (e.g., pembrolizumab, nivolumab) often work better when PD-L1 is present on tumor cells. However, some patients have tumors that are PD-L1 negative, meaning these drugs may be less effective.

**Role of TMB When PD-L1 is Negative**  
- **High TMB:** Research suggests that even if PD-L1 is negative, a high TMB may predict a better response to immunotherapy. This is because the immune system may still recognize and attack tumors with many mutations, even without PD-L1 expression.
- **Low TMB:** If both PD-L1 and TMB are low, the likelihood of responding to immunotherapy is generally lower.

**Clinical Decision-Making**  
- In cases of NSCLC with negative PD-L1, oncologists may consider TMB testing. If TMB is high, immunotherapy (sometimes in combination with other treatments) might still be recommended.
- If TMB is low, other treatment options like chemotherapy or targeted therapy may be preferred.

**Important Note**  
While TMB is a promising biomarker, it is not yet universally used in clinical practice, and guidelines are evolving. Decisions are made based on a combination of factors, including overall health, cancer stage, and other molecular markers.

**Next Steps**  
If you or a loved one is facing this situation, discussing TMB testing and treatment options with your oncology team is important. They can provide personalized recommendations based on the latest research and your specific case.

If you’d like, I can share more about recent advances or support resources for NSCLC patients. Please let me know how I can help further.
2025-08-31 11:59:29,749 INFO User asked: What are the current recommendations for managing immune-related colitis in a patient receiving combination checkpoint inhibitors for metastatic melanoma?
2025-08-31 11:59:29,750 INFO Calling ask_question for sample question...
2025-08-31 11:59:38,189 INFO HTTP Request: POST https://az-openai-cancel-poc-001.openai.azure.com/openai/deployments/gpt-4.1/chat/completions?api-version=2024-08-01-preview "HTTP/1.1 200 OK"
2025-08-31 11:59:38,200 INFO Response received: {'messages': [HumanMessage(content='What are the current recommendations for managing immune-related colitis in a patient receiving combination checkpoint inhibitors for metastatic melanoma?', id='0431c5bf-1e7a-4213-8b80-430e7af440db'), AIMessage(content='Thank you for your thoughtful question. Immune-related colitis is a known side effect of checkpoint inhibitors, especially when used in combination for metastatic melanoma. Managing this condition is important for both patient safety and treatment success.\n\n**Current Recommendations:**\n\n1. **Assessment and Grading:**  \n   - Symptoms can range from mild diarrhea to severe abdominal pain, blood in stool, and dehydration.\n   - Colitis is graded from 1 (mild) to 4 (life-threatening) based on severity.\n\n2. **Initial Steps:**  \n   - For mild symptoms (Grade 1): Supportive care (hydration, anti-diarrheal agents) and close monitoring.\n   - For moderate to severe symptoms (Grade 2 or higher): Withhold checkpoint inhibitors and start further evaluation (stool studies, imaging, possible colonoscopy).\n\n3. **Medical Management:**  \n   - **Moderate to Severe Colitis (Grade 2 or higher):**\n     - Start corticosteroids (e.g., oral prednisone or IV methylprednisolone, typically 1–2 mg/kg/day).\n     - Taper steroids slowly over at least 4–6 weeks once symptoms improve.\n   - If no improvement within 3–5 days, consider additional immunosuppressive therapy (such as infliximab or vedolizumab), but only after ruling out infections.\n\n4. **Infection Exclusion:**  \n   - Always rule out infectious causes (like C. difficile, CMV) before starting immunosuppressive therapy.\n\n5. **Rechallenge and Long-Term Management:**  \n   - Reintroduction of checkpoint inhibitors may be considered in select cases after full resolution, but this should be a careful, multidisciplinary decision.\n   - For recurrent or steroid-refractory colitis, long-term immunosuppression or discontinuation of immunotherapy may be necessary.\n\n6. **Supportive Care:**  \n   - Maintain hydration and nutrition.\n   - Monitor for complications (perforation, sepsis).\n   - Emotional support and clear communication with the patient and caregivers.\n\n**Next Steps:**  \nIf you or someone you care for is experiencing symptoms, it’s important to contact the oncology team promptly. Management should be tailored to the individual, and close monitoring is essential.\n\n**Hopeful Note:**  \nAdvances in supportive care and immunotherapy management have improved outcomes for patients, and most cases of immune-related colitis can be managed effectively with timely intervention.\n\nIf you’d like more detailed guidelines or resources, I can help find them for you. Please let me know if you have any specific concerns or need further information.', response_metadata={'token_usage': {'completion_tokens': 529, 'prompt_tokens': 388, 'total_tokens': 917, 'completion_tokens_details': {'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}, 'prompt_tokens_details': {'audio_tokens': 0, 'cached_tokens': 0}}, 'model_name': 'gpt-4.1-2025-04-14', 'system_fingerprint': 'fp_c79ab13e31', 'prompt_filter_results': [{'prompt_index': 0, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'jailbreak': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}], 'finish_reason': 'stop', 'logprobs': None, 'content_filter_results': {'hate': {'filtered': False, 'severity': 'safe'}, 'protected_material_code': {'filtered': False, 'detected': False}, 'protected_material_text': {'filtered': False, 'detected': False}, 'self_harm': {'filtered': False, 'severity': 'safe'}, 'sexual': {'filtered': False, 'severity': 'safe'}, 'violence': {'filtered': False, 'severity': 'safe'}}}, id='run-6859675f-4232-4a64-9973-09fce921fe2f-0')]}
2025-08-31 11:59:38,202 INFO LLM response: Thank you for your thoughtful question. Immune-related colitis is a known side effect of checkpoint inhibitors, especially when used in combination for metastatic melanoma. Managing this condition is important for both patient safety and treatment success.

**Current Recommendations:**

1. **Assessment and Grading:**  
   - Symptoms can range from mild diarrhea to severe abdominal pain, blood in stool, and dehydration.
   - Colitis is graded from 1 (mild) to 4 (life-threatening) based on severity.

2. **Initial Steps:**  
   - For mild symptoms (Grade 1): Supportive care (hydration, anti-diarrheal agents) and close monitoring.
   - For moderate to severe symptoms (Grade 2 or higher): Withhold checkpoint inhibitors and start further evaluation (stool studies, imaging, possible colonoscopy).

3. **Medical Management:**  
   - **Moderate to Severe Colitis (Grade 2 or higher):**
     - Start corticosteroids (e.g., oral prednisone or IV methylprednisolone, typically 1–2 mg/kg/day).
     - Taper steroids slowly over at least 4–6 weeks once symptoms improve.
   - If no improvement within 3–5 days, consider additional immunosuppressive therapy (such as infliximab or vedolizumab), but only after ruling out infections.

4. **Infection Exclusion:**  
   - Always rule out infectious causes (like C. difficile, CMV) before starting immunosuppressive therapy.

5. **Rechallenge and Long-Term Management:**  
   - Reintroduction of checkpoint inhibitors may be considered in select cases after full resolution, but this should be a careful, multidisciplinary decision.
   - For recurrent or steroid-refractory colitis, long-term immunosuppression or discontinuation of immunotherapy may be necessary.

6. **Supportive Care:**  
   - Maintain hydration and nutrition.
   - Monitor for complications (perforation, sepsis).
   - Emotional support and clear communication with the patient and caregivers.

**Next Steps:**  
If you or someone you care for is experiencing symptoms, it’s important to contact the oncology team promptly. Management should be tailored to the individual, and close monitoring is essential.

**Hopeful Note:**  
Advances in supportive care and immunotherapy management have improved outcomes for patients, and most cases of immune-related colitis can be managed effectively with timely intervention.

If you’d like more detailed guidelines or resources, I can help find them for you. Please let me know if you have any specific concerns or need further information.
